Zupancic Mark, Haeggblom Linnea, Landin David, Marklund Linda, Dalianis Tina, Näsman Anders
Department of Oncology-Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden.
Division of Ear, Nose and Throat Diseases, Department of Clinical Science, Intervention and Technology - CLINTEC, Karolinska Institutet, 171 64 Stockholm, Sweden.
Oncol Lett. 2021 Apr;21(4):277. doi: 10.3892/ol.2021.12538. Epub 2021 Feb 10.
Patients with human papillomavirus-positive (HPV+) base of tongue squamous cell carcinomas (BOTSCC) have an improved survival compared with patients with HPV-negative BOTSCC and it has been suggested that treatment should be tailored. Before individualized treatment can be introduced, additional prognostic markers are required. A prognostic role of psoriasin has previously been demonstrated outside BOTSCC. Therefore, the present study aimed to examine psoriasin in BOTSCC, with focus on HPV+ BOTSCC, in relation to prognosis. A total of 72 BOTSCC samples were stained for psoriasin by immunohistochemistry, and the association between expression and clinical outcomes was analyzed. Patients with low psoriasin expression exhibited significantly improved overall survival (OS; P=0.001) and disease-free survival (DFS; P=0.007), which also was observed in patients with HPV+ BOTSCC (OS, P<0.001; DFS, P=0.02). Furthermore, psoriasin was a significant prognostic factor in univariable and multivariable analyses. In conclusion, psoriasin could be used as a prognostic marker in HPV+ BOTSCC.
与人类乳头瘤病毒阴性（HPV-）的舌底鳞状细胞癌（BOTSCC）患者相比，人类乳头瘤病毒阳性（HPV+）的BOTSCC患者生存率更高，因此有人建议应进行个体化治疗。在引入个体化治疗之前，还需要其他预后标志物。此前已证明牛皮癣素在BOTSCC以外具有预后作用。因此，本研究旨在研究BOTSCC中的牛皮癣素，重点是HPV+BOTSCC，以及其与预后的关系。通过免疫组织化学对总共72份BOTSCC样本进行牛皮癣素染色，并分析表达与临床结果之间的关联。牛皮癣素低表达的患者总生存期（OS；P=0.001）和无病生存期（DFS；P=0.007）显著改善，HPV+BOTSCC患者也观察到这种情况（OS，P<0.001；DFS，P=0.02）。此外，在单变量和多变量分析中，牛皮癣素是一个显著的预后因素。总之，牛皮癣素可作为HPV+BOTSCC的预后标志物。
